Lenalidomide + Dexamethasone + Elotuzumab
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed, Previously Untreated Multiple Myeloma
Conditions
Newly Diagnosed, Previously Untreated Multiple Myeloma
Trial Timeline
Sep 30, 2013 → Jun 25, 2020
NCT ID
NCT01891643About Lenalidomide + Dexamethasone + Elotuzumab
Lenalidomide + Dexamethasone + Elotuzumab is a phase 3 stage product being developed by Bristol Myers Squibb for Newly Diagnosed, Previously Untreated Multiple Myeloma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01891643. Target conditions include Newly Diagnosed, Previously Untreated Multiple Myeloma.
What happened to similar drugs?
0 of 4 similar drugs in Newly Diagnosed, Previously Untreated Multiple Myeloma were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01891643 | Phase 3 | Terminated |
Competing Products
18 competing products in Newly Diagnosed, Previously Untreated Multiple Myeloma